Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. today announced that the first patient has been dosed in the VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of Age-related Macular Degeneration , a leading cause of blindness in adults.